Video
How do you identify patients who could potentially benefit from IL-1 blockade?
Adjunct Prof. Hugues Allard-Chamard
PP-31592
What are the typical clinical manifestations observed in patients with Still’s disease?
Assoc. Prof. Bas Vastert and Prof. Eugen Feist
What is the TTT strategy for managing Still’s disease?
Assoc. Prof. Bas Vastert
Does a ‘window of opportunity’ exist in the treatment of Still’s disease?
Assoc. Prof. Bas Vastert